Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Lymphoma, Non-Hodgkin × Dasatinib × Clear all

Phase

Status

Sponsor Class

OTHER 5 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Ovarian Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Fallopian Tube Neoplasms 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

Etoposide 5 Rituximab 4 Radiotherapy 4 Methotrexate 4 Cytarabine 4 Cyclophosphamide 3 Cisplatin 3 Vincristine 2 Prednisone 2 Peripheral Blood Stem Cell Transplantation 2 Methylprednisolone 2 Gemcitabine 2 Fenretinide 2 Doxorubicin 2 Carmustine 2 tucatinib 1 temsirolimus 1 plerixafor 1 pertuzumab 1 palbociclib 1 olaparib 1 merphos 1 liposomal amphotericin B 1 ibrutinib 1 ibritumomab tiuxetan 1 fludarabine 1 cobimetinib 1 carmustine, poliferprosan 20 drug combination 1 bosutinib 1 axicabtagene ciloleucel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03297606 2026-03-04

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡